USA Archives

Home USA Page 18

Latest Posts

News and Trends 6 Oct 2022

Catawba College and Eremid open genomics lab to offer undergrad training

Catawba College and Eremid Genomic Services, LLC, a genomics contract research provider, are opening the Bill and Shari Graham Genomics Laboratory specializing in genomic sequencing at Eremid's facilities on the…

October 6, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 7 Oct 2022

AI model study may lead to identifying skin cancer from blood test

Researchers have developed an artificial intelligence (AI) model that predicts which skin cancer patients will benefit from a treatment that activates the immune defense system. The scientists are from the…

October 7, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 5 Oct 2022

FDA fast tracks Immutep non-small cell lung cancer candidate

Immutep Limited says the United States Food and Drug Administration (FDA) has granted fast track designation to eftilagimod alpha (efti or IMP321) in combination with pembrolizumab for the treatment of…

October 5, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 5 Oct 2022

New biotech company aims to bridge gap between stem cell research and athletic injuries

Andrews Medicine of Pensacola, Florida, and Celltex Therapeutics Corporation of Houston, Texas, are to form a new biotechnology company to bridge the divide between stem cell research and the current…

October 5, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 5 Oct 2022

OncoSec slashing staff numbers to prioritize pipeline

OncoSec Medical Incorporated is restructuring to prioritize development of its lead clinical candidate TAVO (TAVO-EP). TAVO is a plasmid encoding interleukin 12 (IL-12) delivered by intratumoral electroporation. Oncosec is reducing…

October 5, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

Aeglea BioTherapeutics updates homocystinuria program

Aeglea BioTherapeutics, Inc. says dosing in the third cohort of the phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria is under way. Patients in this cohort…

October 4, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

Lumen Bioscience data show needle free spirulina-produced vaccination protects against malaria

Lumen Bioscience has published data demonstrating a needle-free, spirulina-produced recombinant vaccine that protects against malaria. The research, conducted in collaboration with the University of Washington, was published in the peer-reviewed…

October 4, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

Ginkgo Bioworks acquires Altar and Circularis

Ginkgo Bioworks has announced the acquisition of two biotech companies, Altar, a French firm with a proprietary adaptive evolution platform, and Circularis, which has a proprietary circular RNA and promoter screening…

October 4, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

FDA gives $1.3M grant to Biologics & Biosimilars Collective Intelligence Consortium

The Biologics & Biosimilars Collective Intelligence Consortium (BBCIC) has received a major grant from the Food & Drug Administration (FDA) in support of biosimilars research. The award provides $1.3 million…

October 4, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

Patents granted for Poolbeg Pharma influenza and respiratory virus infections treatments

Poolbeg Pharma has been granted patents by the US Patent and Trademark Office (USPTO) for POLB 001, a small molecule immunomodulator for the treatment of severe influenza and POLB 002,…

October 4, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 3 Oct 2022

Estrella and TradeUP merge to become publicly traded company

Estrella Biopharma, Inc. and TradeUP Acquisition Corp. have entered into a definitive business combination agreement that will result in Estrella becoming a publicly listed company. Upon closing of the transaction,…

October 3, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 3 Oct 2022

Oxford BioTherapeutics enters into antibody agreement with Genmab

Oxford BioTherapeutics (OBT) says Genmab has licensed a novel antibody related to one of OBT's IO programs. The target was discovered using Oxford BioTherapeutics' OGAP drug discovery platform, which incorporates…

October 3, 2022 - 2 minutesmins - By Jim Cornall

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

Download Inpart’s latest report

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inpart, the leading platform for biopharma partnering

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

Download Inpart’s latest report

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inpart, the leading platform for biopharma partnering

Outsourcing in life science R&D today

The Biotech Report 2023

Subscribe to our newsletter to get the latest biotech news!